Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04679090
Other study ID # University Brunswick
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 11, 2018
Est. completion date April 2021

Study information

Verified date February 2021
Source University of New Brunswick
Contact Danielle Bouchard
Phone 5064433908
Email dboucha1@unb.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main objective of our project is to describe what characteristics (e.g., age, current physical activity level) women present when starting the exercise program are potentially associated with an improvement in functional abilities measured with different tests such as the distance you can cover while walking for six minutes.


Description:

The main research objective is to investigate the relationship between baseline physical activity and improvement in physical function, quantified using changes in 6-minute walk test (6MWT) results over the course of the 12-week program. An association is hypothesized to exist between the two variables even when adjusted for weeks into treatment. The goal of the 6MWT is to cover as much distance as possible in six minutes, using as many breaks s necessary. The test is often performed using a 20-meter hallway but requires no specific equipment. A recent study reported that the result of the 6MWT could be used as a measure of the major components of global health in women with breast cancer, making its use in our research especially relevant. Aside from physical functions, baseline characteristics will also be used to determine what characteristics, if any, are associated with health and psychosocial outcomes such as quality of life, social connectedness/support, and mental well-being. The data collected is certain to fill a gap in the literature, and will therefore be likely published in an important journal in the field.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date April 2021
Est. primary completion date April 2021
Accepts healthy volunteers No
Gender Female
Age group 19 Years and older
Eligibility Inclusion Criteria: - Have received a diagnosis of breast cancer in your lifetime - 19 years of age and older - Cleared by medical team to participate in the study - Have the intention to exercise at the facility for the duration of the study Exclusion Criteria: -

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Exercise Program
Participants will exercise twice a week for twelve weeks total.

Locations

Country Name City State
Canada University of Prince Edward Island Charlottetown Prince Edward Island
Canada University of New Brunswick Fredericton New Brunswick
Canada Memorial University of Newfoundland St. John's Newfoundland and Labrador

Sponsors (3)

Lead Sponsor Collaborator
University of New Brunswick Quebec Breast Cancer Foundation, Ultramar

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Walking speed 6-minute walk test (meters walked) Pre and post (after 12 weeks)
Primary Balance One leg stand test (seconds) Pre and post (after 12 weeks)
Primary Strength, Hand grip Amount of force that can be exerted during grip squeeze (kg) Pre and post (after 12 weeks)
Primary Strength, Chair stand test Chair stand test, number of chair stand in 30 seconds Pre and post (after 12 weeks)
Primary Flexibility, back scratch test Back scratch test (cm) Pre and post (after 12 weeks)
Primary Flexibility, sit and reach Sit and reach test Pre and post (after 12 weeks)
Primary Physical Activity Level Pedometer to determine minutes in moderate-vigorous physical activity and steps per day Pre and post (after 12 weeks)
Secondary Attendance Amount of exercise sessions attended during the 12-week program Pre and post (after 12 weeks)
Secondary Weight Weight of individual (kg) Pre and post (after 12 weeks)
Secondary Height Height of individual (cm) Pre and post (after 12 weeks)
Secondary Resting Blood Pressure Systolic and diastolic blood pressure (mmHg) Pre and post (after 12 weeks)
Secondary Resting Heart Rate Resting heart rate (beats per minute) Pre and post (after 12 weeks)
Secondary Body-mass Index Measure of body fat based on height and weight (kg/m^2) Pre and post (after 12 weeks)
Secondary Waist Circumference Measurement around the waist (cm) Pre and post (after 12 weeks)
Secondary FANTASTIC Lifestyle Checklist Meaningful improvement above day-to-day variability on the 6MWT Pre and post (after 12 weeks)
Secondary Functional Assessment of Cancer Therapy General (FACT - G) 27-item questionnaire designed to measure four domains of HRQOL in cancer patients: Physical, social, emotional, and functional well-being Pre and post (after 12 weeks)
Secondary Functional Assessment of Cancer Therapy Fatigue (FACT - F) 40-item measure that assesses self-reported fatigue and its impact upon daily activities and function Pre and post (after 12 weeks)
Secondary Depression Anxiety Stress Scales (DASS) 42-item self report instrument designed to measure the three related negative emotional states of depression, anxiety and tension/stress. Pre and post (after 12 weeks)
Secondary Pittsburgh Sleep Quality Index (PSQI) A self-report questionnaire that assesses sleep quality over a 1-month time interval Pre and post (after 12 weeks)
Secondary Godin-Shephard Leisure-Time Physical Activity Questionnaire Questionnaire used to identify self-reported leisure-time physical activity Pre and post (after 12 weeks)
Secondary Age Age (years) Pre and post (after 12 weeks)
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2